Background The benefit from adjuvant chemotherapy varies among patients with postmenopausal, node-positive, hormone receptor-positive breast cancer. Genomic assays identify patients likely to benefit from chemotherapy but are expensive and tissue consuming. AI-enabled biomarkers may provide scalable alternatives.
AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial
calendar_today
October 23, 2026
person
Thompson, A. M., Meisner, A., Albain, K. S., Tang, C., Biswas, D., Park, J., Zeng, K., Cappadona, J., Liu, C., McClean, A., Berrevoets, J., Bao, L., Machura, B., Witowski, J., Geras, K. J., Speers, C. W., Hayes, D. F., Kalinsky, K., Sharma, P., Rae, J. M., Godwin, A. K.
domain
medrxiv